Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 19:56:101547.
doi: 10.1016/j.gore.2024.101547. eCollection 2024 Dec.

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy

Brittany File  1 , Anjali Hari  2 , Ling Bei  3
Affiliations
Case Reports

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy

Brittany File et al. Gynecol Oncol Rep. .

Abstract

•Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid and lubricating drops.•Dehydrated amniotic membrane patch to treat MIRV related ocular events is a novel therapeutic option.

Keywords: Amniotic membrane patch; Case report; Elahere therapy; Mirvetuximab soravtansine (MIRV); Ocular event.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Canestraro J., Hultcrantz M., Modi S., Hamlin P.A., Shoushtari A.N., Konner J.A., et al. Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates. Cornea. 2022;41 doi: 10.1097/ICO.0000000000002934. - DOI - PMC - PubMed
    1. Corbelli E., Miserocchi E., Marchese A., Giuffre C., Berchicci L., Sacconi R., et al. Ocular toxicity of mirvetuximab. Cornea. 2019;38 doi: 10.1097/ICO.0000000000001805. - DOI - PubMed
    1. Dekaris I., Mravičić I., Barišić A., Drača N., Pauk M. Amniotic membrane transplantation in the treatment of persistent epithelial defect on the corneal graft. Coll. Antropol. 2010;34 - PubMed
    1. Eaton J.S., Miller P.E., Mannis M.J., Murphy C.J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 2015;31 doi: 10.1089/jop.2015.0064. - DOI - PMC - PubMed
    1. Hendershot A., Slabaugh M., Riaz K.M., Moore K.N., O’Malley D.M., Matulonis U., et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023;47 doi: 10.1016/j.gore.2023.101155. - DOI - PMC - PubMed

Publication types

LinkOut - more resources